Compare Organon & Co. Common Stock (OGN) vs Toro Company (The) Common Stock (TTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Toro Company (The) Common Stock — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Toro Company (The) Common Stock trades at $98.27 (market cap $9.27B). The key difference: Toro Company (The) Common Stock is far larger — about 2.6× Organon & Co. Common Stock's market cap, and Toro Company (The) Common Stock pays the higher dividend (1.59%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Toro Company (The) Common Stock for 0 Days on average.
| OGN | TTC | |
|---|---|---|
Market Cap | $3.62B | $9.27B |
Volume | 2,892,999 | 688,325 |
Sector | Health | Industrials |
52-Week High | $13.81 | $101.76 |
52-Week Low | $5.70 | $67.99 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $11.04B | $10.17B |
Dividend Yield | 0.58% | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Toro Company (TTC) trades at $97.88, up 1.27% with strong technical momentum above its 50-day moving average. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.33 beating expectations of $1.31, and raised full-year guidance. Revenue growth of 8.4% in Q3 2026 to $1.23 billion reflects robust demand across professional and residential segments, supported by infrastructure and automation initiatives under new CEO leadership.
Toro presents a balanced investment case with 36% analyst buy ratings and $117.50 price target suggesting 20% upside. However, execution risks from inflation, tariffs, and competitive pressures warrant caution. The stock's premium valuation (P/E 26.17) requires sustained earnings growth, making Q3 2026 results critical for validating current momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Toro Company (The) Common Stock
The Toro Company designs, manufactures, and markets equipment for turf maintenance, snow and ice management, landscaping, construction, and irrigation. Its products serve golf courses, sports fields, and residential and commercial properties in more than 125 countries.
Read more on TTC →
